betway必威登陆网址|betway.com|betway必威亚洲|betway8881

Abstract

WANG Meng, YANG Ji-Yuan. [J]. Journal of International Oncology, 2013, 40(11): 850-853.

［1］ Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet, 2011, 378(9791): 607-620．［2］ Ueno H, Okusaka T, Ikeda M, et al．A phase Ⅰ study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology, 2005, 69(5):421-427．［3］ Ueno H, Okusaka T, Furuse J, et al. Multicenter phase Ⅱ study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastaticpancreatic cancer. Jpn J Clin Oncol, 2011, 41(8):953-958．［4］ Sultana A, Tudur Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary endpoints analyses. Br J Cancer, 2008,99(1):6-13. ［5］ Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19):1817-1825．［6］ Peddi PF, Lubner S, McWilliams R, et al. Multiinstitutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP, 2012, 13(5):497-501．［7］ Cohen SJ, Dobelbower R Jr, Lipsitz S, et al. A randomized phase Ⅲ study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys, 2005, 62(5):1345-1350．［8］ Chauffert B, Mornex F, Bonnetain F, et al. Phase Ⅲ trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Ann Oncol, 2008, 19(9):1592-1599．［9］ Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus Gemcitabine plus Radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial. J Clin Oncol, 2011, 29(31):4105-4112．［10］ Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine based or capecitabine based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP):a multicentre, randomised, phase 2 trial. Lancet Oncol, 2013, 14(4):317-326．［11］ Shinchi H, Maemura K, Mataki Y, et al. A phase Ⅱ study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally　advanced pancreatic cancer．J Hepatobiliary Pancreat Sci, 2012, 19(2):152-158．［12］ Kim HM， Bang S， Park JY， et al． Phase Ⅱ trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.Cancer Chemother Pharmacol， 2009，63(3):535-541. ［13］ Shinchi H， Maemura K， Mataki Y， et al． A phase Ⅱ study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S1 alone for locally　advanced pancreatic cancer．J Hepatobiliary Pancreat Sci， 2012，19(2):152-158．［14］ Crane CH， Winter K， Regine WF， et al． Phase Ⅱ study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabineand bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411．J Clin Oncol， 2009，27(25):4096-4102．［15］ Xiong HQ， Rosenberg A， LoBuglio A， et al． Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase Ⅱ Trial. J Clin Oncol， 2004，22(13):2610-2616．［16］ Philip PA, Benedetti J, Corless CL, et al． Phase Ⅲ study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Groupdirected intergroup trial S0205. J Clin Oncol， 2010，28(22):3605-3610．［17］ Strumberg D， Schultheis B， Scheulen ME， et al． Phase Ⅱ study of nimotuzumab, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer． Invest New Drugs， 2012，30(3):1138-1143. ［18］ Strumberg D， Schultheis B， Scheulen ME， et al． Safety,efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody,in patients with locally advanced or metastatic pancreatic cancer． Int J Clin Pharmacol Ther， 2010，48(7):473-475．［19］ Crane CH, Mason K, Janjan NA, et al． Initial experience combining cyclooxygenase2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol， 2003，26(4)：S81-S84．［20］ Xiong HQ， Rosenberg A， LoBuglio A， et al. Cetuximab,a monoclonal antibody targeting the epidermal growth factor receptor, in combination withgemcitabine for advanced pancreatic cancer: a multicenter phase Ⅱ Trial．J Clin Oncol， 2004，22(13):2610-2616．［21］ Ferrari V， Valcamonico F， Amoroso V， et al． Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase Ⅱ trial. Cancer Chemother Pharmacol， 2006，57(2):185-190.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version）[J]. Journal of International Oncology, 2023, 50(4): 193-201.
[14]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng.Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance[J]. Journal of International Oncology, 2023, 50(4): 227-230.
[15]	Shi Xaioqi, Wang Hongyan.Research progress on the interaction between gut microbiota and radiation enteritis[J]. Journal of International Oncology, 2023, 50(4): 244-247.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments